 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...4950515253545556575859...132133» |
- Xeljanz (tofacitinib) / Pfizer
[VIRTUAL] Uncoupling of T-cell bispecific antibody-induced cytokine release and cytotoxicity revealed by differential activities of mTOR, JAK1/2 and Src inhibitors. (eTalks Room) - May 11, 2021 - Abstract #CIMT2021CIMT_147;
The Src inhibitor dasatinib could rather stand as a potential antidote for on-target off-tumor activity or high-grade CRS. The data are being validated in vivo.
- || Avastin (bevacizumab) / Roche
Clinical, Review, Journal: Colorectal Large-Cell Neuroendocrine Carcinoma: Case Report and Literature Review for Potential Novel Therapeutic Options. (Pubmed Central) - May 11, 2021
The data are being validated in vivo. No abstract available
- || everolimus / Generic mfg., exemestane / Generic mfg.
Clinical, Journal: Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC. (Pubmed Central) - May 11, 2021
P3
POC did not influence the prognosis of estrogen receptor-positive metastatic breast cancer patients. Patients with non-visceral metastasis, a BMI < 25 mg/m, and who did not receive BMA while receiving EVE and EXE may have better prognoses.
- | everolimus / Generic mfg., sorafenib / Generic mfg.
Trial primary completion date, Metastases: A091302: Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer (clinicaltrials.gov) - May 11, 2021
P2, N=35, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Patients with non-visceral metastasis, a BMI < 25 mg/m, and who did not receive BMA while receiving EVE and EXE may have better prognoses. Trial primary completion date: Aug 2021 --> Jan 2021
- ||| Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead
According to @stolaney1 stomatitis/mucositis responds to steroid mouthwash (a la SWISH study for everolimus). Activity in sacituzumab refractory is intriguing. Excited about upcoming Tropion study @UCSFCancer @OncoAlert #ESMOBreast21 (Twitter) - May 9, 2021
- |||| Keytruda (pembrolizumab) / Merck (MSD), Sutent (sunitinib) / Pfizer
Toni K. Choueiri, MD, on RCC: Treatment With Lenvatinib Plus Pembrolizumab or Everolimus vs Sunitinib https://t.co/nBDbphwu1r #GU21 #kcsm #oncology #cancer @DrChoueiri @DanaFarberNews (Twitter) - May 8, 2021
- ||| everolimus / Generic mfg.
.@ABhealer108 — what prophylactic strategies could decrease that 63% stomatitis? Steroids À la everolimus? (Twitter) - May 8, 2021
- || cyclosporine / Generic mfg.
Clinical, Journal: Analysis of neoplastic skin complications in transplant patients: experience of an italian multidisciplinary transplant unit. (Pubmed Central) - May 7, 2021
Trial primary completion date: Aug 2021 --> Jan 2021 This study demonstrated the increased risk of skin cancer in transplant patients during the first 7 years of follow-up and made the dermatologists aware about the need of a regular cutaneous follow-up for this subset of patients.
- || cyclosporine / Generic mfg., tacrolimus XR / Generic mfg.
Clinical, Observational data, Journal: Prospective single-centre clinical observational study on electronically monitored medication non-adherence, its psychosocial risk factors and lifestyle behaviours after heart transplantation: a study protocol. (Pubmed Central) - May 7, 2021
The results of this study will be published in peer-reviewed journals and presented at conferences. DRKS00020496.
- | veliparib (ABT-888) / AbbVie, Mekinist (trametinib) / Novartis, BeiGene, adavosertib (AZD1775) / AstraZeneca
Trial primary completion date, Metastases: MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations (clinicaltrials.gov) - May 7, 2021
P2, N=700, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
DRKS00020496. Trial primary completion date: May 2021 --> May 2022
- | cyclosporine / Generic mfg.
Journal: Significance of ethnic factors in immunosuppressive therapy management after organ transplantation. (Pubmed Central) - May 6, 2021
Thus, ethnic considerations might provide useful information for optimizing individualized immunosuppressive therapy after organ transplantation. Here, we review ethnic factors affecting the pharmacokinetics of immunosuppressive drugs requiring therapeutic drug monitoring, including tacrolimus, cyclosporine, mycophenolate mofetil, sirolimus, and everolimus.
- | everolimus / Generic mfg.
Journal: Long-Term Performance of Laboratory-Developed Liquid Chromatography-Tandem Mass Spectrometry Tests and a Food and Drug Administration-Approved Immunoassay for the Therapeutic Drug Monitoring of Everolimus. (Pubmed Central) - May 6, 2021
Initially, QMS everolimus concentrations in patient samples were comparable with those detected in LC-MS/MS laboratories. However, concentration bias of the QMS assay significantly changed within 6 years, emphasizing the need for long-term, independent performance tracking of therapeutic drug monitoring assays, including FDA-approved assays.
- || Enrollment closed, Real-world evidence, Real-world, Metastases: Treat ER+ight: Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy (clinicaltrials.gov) - May 6, 2021
P=N/A, N=438, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
However, concentration bias of the QMS assay significantly changed within 6 years, emphasizing the need for long-term, independent performance tracking of therapeutic drug monitoring assays, including FDA-approved assays. Recruiting --> Active, not recruiting
- | LCL161 / Novartis, spartalizumab (PDR001) / Novartis
Trial completion date, Combination therapy: A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (clinicaltrials.gov) - May 5, 2021
P1, N=315, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial completion date: Sep 2021 --> Aug 2022
- | everolimus / Generic mfg.
Journal: Combining Everolimus and Ku0063794 Promotes Apoptosis of Hepatocellular Carcinoma Cells via Reduced Autophagy Resulting from Diminished Expression of miR-4790-3p. (Pubmed Central) - May 4, 2021
It was also found that HCC tissues were characterized by higher expression of miR-4790-3p and lower expression of ZNF225; HCC tissues were also characterized by higher autophagic flux. We, thus, conclude that the potentiated anticancer effect of the everolimus and Ku0063794 combination therapy is strongly associated with reduced autophagy resulting from diminished expression of miR-4790-3p, as well as higher expression of ZNF225.
- || Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion, Metastases: Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer (clinicaltrials.gov) - May 4, 2021
P1, N=38, Completed, Sponsor: SCRI Development Innovations, LLC
We, thus, conclude that the potentiated anticancer effect of the everolimus and Ku0063794 combination therapy is strongly associated with reduced autophagy resulting from diminished expression of miR-4790-3p, as well as higher expression of ZNF225. Active, not recruiting --> Completed
- | everolimus / Generic mfg.
Enrollment change, Trial withdrawal: EVEROST: Topical Everolimus in Patients With Tuberous Sclerosis Complex (clinicaltrials.gov) - May 3, 2021
P2/3, N=0, Withdrawn, Sponsor: Hospices Civils de Lyon
Active, not recruiting --> Completed N=96 --> 0 | Not yet recruiting --> Withdrawn
- |||||||||| Ostarine (enobosarm) / Veru Inc
New P3 trial, Monotherapy, Metastases: ARTEST: Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer (clinicaltrials.gov) - May 2, 2021
P3, N=210, Not yet recruiting, Sponsor: Veru Inc.
- || everolimus / Generic mfg., sirolimus / Generic mfg.
Clinical, Journal: Compassionate use of everolimus for refractory epilepsy in a patient with MTOR mosaic mutation. (Pubmed Central) - May 1, 2021
Though the physiopathological rationale was good, no significant clinical response was noticed under everolimus treatment. A clinical trial would be needed to draw conclusions, but, because the phenotype is extremely rare, it would certainly need to be conducted on an international scale.
- || Review, Journal, IO biomarker: Targeted Cancer Therapy: What's New in the Field of Neuroendocrine Neoplasms? (Pubmed Central) - May 1, 2021
Despite recent therapeutic achievements, thus, systemic treatment options remain limited. In this review we will discuss the state-of-the-art targeted therapies in the field of NETs, and also future perspectives of novel therapeutic drugs or strategies in clinical development, including recently presented results from randomized trials of yet unapproved antiangiogenic agents (i.e., pazopanib, surufatinib and axitinib), PRRT including both approved radiopharmaceuticals (177Lu-Oxodotreotide) and others in development (177Lu-Edotreotide, 177Lu-Satoreotide Tetraxetan), immunotherapy and other innovative targeted strategies (antibody-drug conjugates, bites,…) that shall soon improve the landscape of personalized treatment options in NET patients.
- | navitoclax (ABT 263) / AbbVie, Roche
Journal: Autofluorescence Imaging of Treatment Response in Neuroendocrine Tumor Organoids. (Pubmed Central) - May 1, 2021
In one of the non-responsive PDCO lines, heterogeneous response was identified with two distinct subpopulations of cell metabolism. Overall, this work shows that OMI provides single-cell metabolic measurements of drug response in PDCOs to guide drug development for GEP-NET patients.
- | Opdivo (nivolumab) / Ono Pharma, BMS
Journal, PD(L)-1 Biomarker: Novel Insights into Diagnosis, Biology and Treatment of Primary Diffuse Leptomeningeal Melanomatosis. (Pubmed Central) - May 1, 2021
Last, we use a unique patient derived PDLMM cell model to provide first insights into in vitro drug sensitivities. In summary, we provide future diagnostic and therapeutic guidance for PDLMM and first insights into the use of liquid biopsy and in vitro models for this orphan cancer type.
- || temozolomide / Generic mfg.
Clinical, P2 data, Journal, PARP Biomarker: Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial. (Pubmed Central) - May 1, 2021
Further investigation, better annotation of predictive biomarkers, and the development of more effective agents are necessary to inform treatment decisions in an era of precision cancer medicine. Increasing prevalence of tumor mutation profiling and preference for targeted therapy make it difficult to use a randomized phase II design to evaluate targeted therapy efficacy in an advanced disease setting.
- || everolimus / Generic mfg.
Biomarker, Clinical, P2 data, Journal: Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer. (Pubmed Central) - Apr 30, 2021
Everolimus demonstrated predictable toxicity in advanced and heavily pretreated patients with mCRPC. No clinical or clear pathologic effects despite downstream TORC1 target inhibition, suggesting that single agent everolimus has no clinical utility in men with mCRPC.
- |||| everolimus / Generic mfg., tacrolimus oral / Generic mfg.
New P4 trial: STELLA: Efficacy and Safety of CertiroBell® Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant Recipients (clinicaltrials.gov) - Apr 30, 2021
P4, N=112, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- || Inlyta (axitinib) / Pfizer
Biomarker, Clinical, Journal: Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. (Pubmed Central) - Apr 30, 2021
Leave-one-out experiments demonstrated significant concordance between observed and DDPP-predicted PFS (r = 0.9, p = 0.015) for patients treated with everolimus. Notwithstanding the small cohort and pending further prospective validation, the prototype of DDPP offers the potential to transform patients' treatment selection with a tumor- and treatment-agnostic predictor of outcomes (duration of PFS).
- Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Real-world risk of anosmia with cancer directed systemic therapy: A pharmacovigilance assessment using FDA Adverse Events Reporting System (FAERS) database. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4918;
It is worth noting that none of the suspect medications identified in this study have anosmia listed as known adverse reaction on accompanying package insert . Further studies need to be conducted to confirm if causal relationship exists between use of these drugs and olfactory function compromise.
- everolimus / Generic mfg.
[VIRTUAL] Covid-19 infection in patients with a history of everolimus use. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4878;
In our study, we found that 10% of our patients had COVID infection and 2 of our patients died due to COVID-19 . In the group that discontinued everolimus treatment for a year or more, 1 patient died due to COVID-19, and 1 patient in the group still receiving everolimus treatment .
- Opdivo (nivolumab) / Ono Pharma, BMS, Sutent (sunitinib) / Pfizer, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Sunitinib in metastatic clear cell renal cancer (CCRC): A real life Chilean single institution experience. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4483;
Subsequent therapies consisted of pazopanib (25 patients), axitinib (17 patients), everolimus (9 patients), nivolumab (6 patients) and cabozantinib (1 patient) . Sunitinib is a good choice in low-risk metastatic CCRC and we adopted this regimen as standard therapy in this group of patients at our Institution.
- hydroxychloroquine / Generic mfg.
[VIRTUAL] INTENSIVE: InterNaTional rEgistry oN Sars-cov-2 posItiVe nEuroendocrine neoplasm patients. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4360;
No clear correlations were observed with type, primary site and treatment of NEN . The recruitment is ongoing.
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Dual immune checkpoint blockade in advanced well-differentiated neuroendocrine tumors, a phase II clinical trial. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4356;
P2
The impressive ORR of 44% with a median duration of response exceeding 15 months in this small clinical trial warrants further study of combination CTLA-4 and PD-1 inhibition in previously treated well-differentiated NET . Our ongoing immunologic and genomic correlative analysis in responders and non-responders will help inform future study of immunotherapy in this patient population in need of new systemic therapy approaches.
- ENMD-2076 / CASI, Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre
[VIRTUAL] Computational extraction and analysis of de-identified medical records to characterize hyperammonemia in patients with fibrolamellar carcinoma (FLC). () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4326;
Herein, we have defined hyperammonemia as a frequent event in FLC, not directly linked to hepatic dysfunction or individual therapies . Further investigation may determine whether hyperammonemia is related to FLC tumor biology.
- everolimus / Generic mfg.
[VIRTUAL] Efficacy of everolimus-containing chemotherapy in HER2 negative metastatic breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_3754;
TNBC patients had a trend of longer mPFS than HR+ patients . And the patients carrying other mutations besides PIK3CA in the PI3K/AKT/mTOR pathway have a trend of longer PFS and higher DCR compared to the patients without other mutations .
- everolimus / Generic mfg.
[VIRTUAL] The effect of everolimus on body composition (BC) in patients with metastatic breast cancer (MBC). () - Apr 29, 2021 - Abstract #ASCO2021ASCO_3718;
Everolimus is associated with decrease in SAT, with no significant change in VAT, SMA, or SMD . Further investigation is required to determine if these changes are associated with disease outcomes or everolimus toxicities.
- everolimus / Generic mfg., fulvestrant / Generic mfg.
[VIRTUAL] Everolimus combined with endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: A retrospective study. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_3715;
Everolimus combined with fulvestrant is not superior to everolimus combined with AI in HR-positive, HER2-negative breast cancer patients . For postmenopausal patients, patients without bone metastasis, and patients with visceral disease, everolimus combined with AI is a better choice.
- everolimus / Generic mfg., exemestane / Generic mfg.
[VIRTUAL] Everolimus and exemestane in hormone receptor-positive advanced breast cancer: A comprehensive cancer center’s experience. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_3709;
Our results confirm the effectiveness and safety of everolimus/exemestane in real-world setting and support its use mainly before palliative ChT . Everolimus/exemestane in HR+ ABC is feasible in the clinic, with toxicity manageable under close surveillance.
- paclitaxel / Generic mfg., docetaxel / Generic mfg.
[VIRTUAL] Micro-organospheres: An automated patient-derived model platform for rapid drug screening of breast cancer. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_3693;
We have now shown the feasibility of establishing micro-organospheres as a rapid, scalable, and cost-effective platform to study patient-derived BC drug response . This technology has the potential to be used for both diagnostics to guide patient treatment and as a screening platform for new BC drug discovery.
- ||||| Sutent (sunitinib) / Pfizer
Clinical: Patients with metastatic non-clear cell #renalcellcarcinomas exhibit several poor prognosis angiokines and immunomodulatory chemokines on treatment with sunitinib or everolimus. Study by @WalterStadler5 and colleagues in @CCR_AACR #AnswerCancer https://t.co/SnO1ZoGDVF (Twitter) - Apr 29, 2021
- || everolimus / Generic mfg.
Clinical, P2 data, Journal: A Phase II Study of Continuous Oral mTOR Inhibitor Everolimus for Recurrent, Radiographic-Progressive Neurofibromatosis Type 1-Associated Pediatric Low-Grade Glioma: A Neurofibromatosis Clinical Trials Consortium Study. (Pubmed Central) - Apr 29, 2021
Individuals with recurrent/progressive NF1-associated LGG demonstrate significant disease stability/shrinkage during treatment with oral everolimus with a well-tolerated toxicity profile. Everolimus is well-suited for future consideration as upfront or combination therapy in this patient population.
- everolimus / Generic mfg.
[VIRTUAL] Racial disparities in second-line (2L) treatment and overall survival among patients (pts) with hormone receptor positive HER2 negative (HR+HER2-) metastatic breast cancer (mBC) treated in routine practice. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_3083;
In addition, AA pts had worse rwOS than White pts even after receiving 2L CDKi among those who did not receive 1L CDKi . This disparity was not observed among patients who received 1L CDKi.
- Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Randomized phase II study of sorafenib with or without everolimus in patients with radioactive iodine refractory Hürthle cell thyroid cancer (HCC) (Alliance A091302/ ITOG 1706). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2531;
P2
PFS was improved with the addition of E to S in this small randomized multi-institutional phase II study done . Accrual was difficult, but these promising results suggest that this combination should be further studied.
- sapanisertib (TAK-228) / Takeda, serabelisib (MLN1117) / Takeda, Petra Pharma
[VIRTUAL] Final results of phase 1 evaluation of the safety and clinical activity of sapanisertib in combination with serabelisib and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2185;
P1
There were few serious adverse events, and most side effects were managed with routine supportive care interventions . Preliminary clinical results appear very promising, especially for patients with PI3K/AKT/mTOR pathway mutations .
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2107;
P2, P3
Secondary efficacy end points for this study are clinical benefit rate, disease control rate, duration of response, progression-free survival, overall survival, and safety . Tertiary/exploratory end points are biomarker analysis and association with clinical response/disease etiopathogenesis.
- Sutent (sunitinib) / Pfizer
[VIRTUAL] Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2074;
P3
In the CLEAR study, LEN + EVE met the primary endpoint of a significant benefit in PFS vs SUN . The results of these exploratory analyses suggest that subsequent systemic anticancer therapy affected the OS outcome results for LEN + EVE vs SUN in the CLEAR study.
- Keytruda (pembrolizumab) / Merck (MSD), Sutent (sunitinib) / Pfizer
[VIRTUAL] Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2072;
P3
In pts with target kidney lesions, LEN + PEMBRO conferred survival benefits vs SUN similar to benefits observed in the overall population . Overall, pts treated with LEN + PEMBRO who had greater than 75% reduction in target lesions had similar OS rates to pts with CR.
- Inlyta (axitinib) / Pfizer, Bavencio (avelumab) / EMD Serono, Pfizer, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Outcomes of patients who progressed while receiving avelumab + axitinib (A + Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2025;
P3
The most common 2L SA was cabozantinib (60/163), and the most frequent 2L CT was everolimus + lenvatinib (12/41)... In patients with aRCC who received 2L CT following 1L treatment with A + Ax, long-term OS and PFS2 were observed.
- vorolanib (X-82) / Tyrogenex
[VIRTUAL] Vorolanib, everolimus, and the combination in patients with pretreated metastatic renal cell carcinoma (CONCEPT study): A randomized, phase 3, double-blind, multicenter trial. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2022;
P3
This is the first phase 3 study of combination of mTOR- and VEGF-targeted agents in second-line treatments . Vorolanib plus everolimus showed a PFS benefit for patients with metastatic RCC who have progressed after one previous VEGF-targeted therapy with a safe tolerance profile.
- Keytruda (pembrolizumab) / Merck (MSD), Sutent (sunitinib) / Pfizer
[VIRTUAL] Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2005;
P3
Vorolanib plus everolimus showed a PFS benefit for patients with metastatic RCC who have progressed after one previous VEGF-targeted therapy with a safe tolerance profile. Compared with SUN, pts in LEN + PEMBRO group had similar or better symptoms and HRQoL.
- vistusertib (AZD2014) / AstraZeneca
[VIRTUAL] Multi-center, single arm phase II study of the dual mTORC1/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1953;
P2
The follow-up data continue to mature . Adverse events were tolerable in this patient population .
- Signifor LAR (pasireotide long acting release) / Novartis
[VIRTUAL] First long-term results on efficacy and safety of long-acting pasireotide in combination with everolimus in patients with advanced carcinoids (NET) of the lung/thymus: Phase II LUNA trial. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1786;
P2
The safety and tolerability profile of PAS and EVE alone or in combination were consistent with prior experience of these treatments in the oncology setting, with no new safety signals being reported during the study . Post-hoc prognostic studies are ongoing.